$1312.30-14.02 (-1.06%)
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. in the Healthcare sector is trading at $1,312.30 with a market capitalization of $27.0B. Wall Street consensus targets $1,451.92 (13 analysts), implying a +10.6% move over the next 12 months. The stock is currently 14% below its 52-week high of $1,525.17, remaining 0.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.03B↑ | $947.13M↓ | $1.13B↑ | $1.03B↑ | $983.22M |
| Gross Profit | $650.22M↑ | $555.82M↓ | $675.43M↑ | $609.46M↑ | $579.88M |
| Operating Income | $314.47M↑ | $226.60M↓ | $343.34M↑ | $289.90M↑ | $265.71M |
| Net Income | $232.90M↑ | $169.45M↓ | $285.76M↑ | $217.49M↑ | $202.35M |
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chin...
Investing.com -- Mettler-Toledo faces a growing mismatch between its premium valuation and a more modest growth outlook as competition intensifies across its weighing and laboratory businesses, brokerage Redburn said on Wednesday, initiating coverage of the precision-instrument maker with a Sell rating.

Mettler-Toledo has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Mettler-Toledo (MTD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

Bank of America, Mettler-Toledo and VSE post strong gains as Zacks' Focus List, ECAP and Top 10 picks outperform.
Academic risk and quality models computed from MTD's own filings and price history, not from analyst opinion.
Mixed: 5 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 26.6% reading.
Fama-French 5-factor market beta. The five factors explain 23% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.